Enhancement of mammary tumor formation in mice by a cytostatic drug, melphalan
Medina, D.
Cancer Research 37(1): 317-319
1977
ISSN/ISBN: 0008-5472 PMID: 830417 Document Number: 110070
Melphalan (L-phenylalanine mustard), a cytostatic drug used in treatment of human breast cancer, was injected into mice bearing preneoplastic hyperplastic alveolar nodule mammary outgrowth line D2. Melphalan, doses of either 2.5 or 5.0 mg/kg, markedly enhanced tumor formation in its mammary nodule outgrowth line. Samples of nodule outgrowths in untreated mice produced 13% tumors by 9 months after transplantation, whereas nodule outgrowths in melphalan-treated mice produced 57 and 85% mammary tumors in the lower and higher dose groups, respectively.
Document emailed within 1 workday
Related Documents
Kurata, S.; Tsuchiya, T.; Norimura, T.; Yamashita, U. 1983: Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice Journal of Immunology 130(1): 496-500Adler, A.; Keisari, Y.; Ofir, R. 1985: Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy Journal of the National Cancer Institute 74(2): 429-436
Kennel, S.J.; Lankford, T.K.; Ullrich, R.L.; Jamasbi, R.J. 1988: Enhancement of lung tumor colony formation by treatment of mice with monoclonal antibodies to pulmonary capillary endothelial cells Cancer Research 48(17): 4964-4968
Mitani, M.; Mori, K.; Himeno, K.; Nomoto, K. 1989: Anti-tumor cytostatic mechanism and delayed-type hypersensitivity against a syngeneic murine tumor. Comparison between neonatally thymectomized mice and congenitally athymic nude mice Journal of Immunology 142(6): 2148-2154
Faulkin, L.J.; Mitchell, D.J.; Young, L.J.; Morris, D.W.; Malone, R.W.; Cardiff, R.D.; Gardner, M.B. 1984: Hyperplastic and neoplastic changes in the mammary glands of feral mice free of endogenous mouse mammary tumor virus provirus Journal of the National Cancer Institute 73(4): 971-982
Omer, C.A.; Chen, Z.; Diehl, R.E.; Conner, M.W.; Chen, H.Y.; Trumbauer, M.E.; Gopal-Truter, S.; Seeburger, G.; Bhimnathwala, H.; Abrams, M.T.; Davide, J.P.; Ellis, M.S.; Gibbs, J.B.; Greenberg, I.; Koblan, K.S.; Kral, A.M.; Liu, D.; Lobell, R.B.; Miller, P.J.; Mosser, S.D.; O'Neill, T.J.; Rands, E.; Schaber, M.D.; Senderak, E.T.; Oliff, A.; Kohl, N.E. 2000: Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor Cancer Research 60(10): 2680-2688
Erber, S.; Ringshandl, R.; Von Angerer, E. 1991: 2-Phenylbenzo[b]furans: relationship between structure, estrogen receptor affinity and cytostatic activity against mammary tumor cells Anti-Cancer Drug Design 6(5): 417-426
Mokyr, M.B.; Barker, E.; Weiskirch, L.M.; Takesue, B.Y.; Pyle, J.M. 1989: Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor Cancer Research 49(16): 4597-4606
Hall, A.G.; Matheson, E.; Hickson, I.D.; Foster, S.A.; Hogarth, L. 1994: Purification of an alpha class glutathione S-transferase from melphalan-resistant Chinese hamster ovary cells and demonstration of its ability to catalyze melphalan-glutathione adduct formation Cancer Research 54(13): 3369-3372
Rubin, M.; Bluestone, J.A.; Newell, K.A.; Prokhorova, A.; Mokyr, M.B. 1994: Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases Journal of Immunology 152(7): 3522-3529
Slagle, B.L.; Medina, D.; Butel, J.S. 1987: Mammary cancer stages in BALB/cV mice: mouse mammary tumor virus expression and virus-host interactions Journal of the National Cancer Institute 79(2): 323-335
Plata, F. 1985: Enhancement of tumor growth correlates with suppression of the tumor-specific cytolytic T lymphocyte response in mice chronically infected by Trypanosoma cruzi Journal of Immunology 134(2): 1312-1319
Fine, D.L.; Arthur, L.O.; Gardner, M.B. 1978: Prevalence of murine mammary tumor virus antibody and antigens in normal and tumor-bearing feral mice Journal of the National Cancer Institute 61(2): 485-491
Iunker, V.M.; Arkhipov, S.A.; Gruntenko, E.V. 1984: Ambiguous action of splenocytes from tumor-bearing mice on the formation of metastases in the lungs of mice in an adaptive transfer system Biulleten' Eksperimental'noi Biologii i Meditsiny 98(11): 598-600
Mohr, S.J.; Chirigos, M.A.; Fuhrman, F.; Smith, G. 1976: Enhancement of a tumor allograft in BALB/c x DBA/2 F1 mice by pyran copolymer Cancer Research 36(4): 1315-1319
Vistica, D.T.; Rabon, A.; Rabinovitz, M. 1978: Enhancement of melphalan therapy with glutaminase:asparaginase Research Communications in Chemical Pathology and Pharmacology 22(1): 83-92
Lopez, D.M.; Sigel, M.M.; Charyulu, V.L. 1981: Kinetics of responses to tumor antigens and mouse mammary tumor virus in BALB/cCrgl and BALB/cfC3H mice Journal of the National Cancer Institute 66(1): 191-196
Bober, L.A.; Kranepool, M.J.; Bojko, C.; Steiner, G.; Hollander, V.P. 1976: Endotoxin enhancement of plasma cell tumor development in mice given injections of mineral oil Cancer Research 36(6): 1947-1949
Zurborn, K.H.; Sondermann, I.; Gross, W.L. 1985: Decrease of paraprotein secretion despite progressive tumor cell proliferation by cytostatic drug therapy of plasmacytoma Der Internist 26(9): 584-586
Kramarsky, B.; Lasfargues, E.Y.; Moore, D.H. 1970: Ultrastructural and quantitative studies of mammary tumor virus production in cultured mouse mammary tumor cells Cancer Research 30(4): 1102-1108